Tissue Regenix Share Discussion Threads

[zinzanno8] 30/6/2017 15:29

It was published at the end of the FY16 results PDF...Bit sneaky really

[channel pirate] 30/6/2017 15:26

Thank you zinzanno8,

Where was that published ? I looked on the Companies Calendar and it still states AGM July 2017.

[zinzanno8] 30/6/2017 15:05

Notice is given that the 2017 annual general meeting of Tissue Regenix Group plc (“Company̶1;) will be held at DLA Piper UK LLP, Princes
Exchange, Princes Square, Leeds LS1 4BY on 30 June 2017 at 10.00 a.m. for the following purposes:
To consider and, if thought fit, to pass the following resolutions as ordinary resolutions:
1. To receive the Company’s annual accounts, strategic report and directors’ and auditors’ reports for the 11 month period ended 31
December 2016.
2. To appoint Paul John Devlin as a director of the Company.
3. To reappoint Alan Miller, who retires by rotation, as a director of the Company.
4. To reappoint Antony Odell, who retires by rotation, as a director of the Company.
5. To reappoint John Samuel, who retires by rotation, as a director of the Company.
6. To reappoint KPMG LLP as auditors of the Company.
7. To authorise the directors to determine the remuneration of the auditors.
8. That, pursuant to section 551 of the Companies Act 2006 (“Act”), the directors be generally and unconditionally authorised to allot
Relevant Securities:
8.1 up to an aggregate nominal amount of £1,269,033; and
8.2 comprising equity securities (as defined in section 560(1) of the Act) up to a further aggregate nominal amount of £1,269,033 in
connection with an offer by way of a rights issue:
8.2.1 to holders of ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers
of ordinary shares held by them; and
8.2.2 to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to
such rights, as the directors otherwise consider necessary,
but subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to treasury
shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of
any regulatory body or stock exchange,
provided that these authorities shall expire at the conclusion of the next annual general meeting of the Company after the passing
of this resolution or on 30 September 2018 (whichever is the earlier), save that, in each case, the Company may make an offer or
agreement before the authority expires which would or might require Relevant Securities to be allotted after the authority expires and
the directors may allot Relevant Securities pursuant to any such offer or agreement as if the authority had not expired.
In this resolution, “Relevant Securities” means shares in the Company or rights to subscribe for or to convert any security into
shares in the Company; a reference to the allotment of Relevant Securities includes the grant of such a right; and a reference to the
nominal amount of a Relevant Security which is a right to subscribe for or to convert any security into shares in the Company is to the
nominal amount of the shares which may be allotted pursuant to that right.
To consider and, if thought fit, to pass the following resolutions as special resolutions:
9. That, subject to the passing of resolution 8 and pursuant to section 570 of the Act, the directors be and are generally empowered
to allot equity securities (within the meaning of section 560 of the Act) for cash pursuant to the authority granted by resolution 8 as
if section 561(1) of the Act did not apply to any such allotment, provided that this power shall be limited to the allotment of equity
securities:
9.1 in connection with an offer of equity securities (whether by way of a rights issue, open offer or otherwise):
9.1.1 to holders of ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers
of ordinary shares held by them; and
9.1.2 to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to
such rights, as the directors otherwise consider necessary,
but subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to treasury
shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of
any regulatory body or stock exchange; and
9.2 otherwise than pursuant to paragraph 9.1 of this resolution up to an aggregate nominal amount of £380,709,
and this power shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution
or on 30 September 2018 (whichever is the earlier), save that the Company may make an offer or agreement before this power
expires which would or might require equity securities to be allotted for cash after this power expires and the directors may allot equity
securities for cash pursuant to any such offer or agreement as if this power had not expired.
This power is in substitution for all existing powers under section 570 of the Act (which, to the extent unused at the date of this
resolution, are revoked with immediate effect).
By order of the board
PAUL DEVLIN
COMPANY SECRETARY
2 June 2017

[channel pirate] 30/6/2017 14:09

So much for the Companies web-page advising us the AGM will be held July 2017 - Anyone know what the Resolutions were ?


Fri, 30th Jun 2017 12:00

RNS Number : 7516J

Tissue Regenix Group PLC

30 June 2017

Tissue Regenix Group plc

Result of AGM

Leeds, 30 June 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

[channel pirate] 22/6/2017 09:52

With the share price having lost just over 35.36% in the last 6 months, then we could do with some good supporting news right now, or like "yesterday" and not "tomorrow".

I have built a nice size holding during these past 6 months, but will not be panic selling or adding more until we get some positive news from the company.

[bamboo2] 09/6/2017 11:12

Partly agree with you Andrew. I think turnover is the key though.

[andrewbaker] 09/6/2017 11:06

Further to my post number 1893, the results are both heartening and disappointing. Whilst the product is good, the execution is poor. The bosses seem more concerned with spending money on staff (and themselves?) at the expense of profitability. More economic good management is called for. It's obviously not just big established businesses that can milk a company it seems. I just hope that decent management can somehow take over here and build what should be a growing profitable business, with due concern for shareholders, who at the end of every day, are the owners: staff are not!

[channel pirate] 03/6/2017 22:37

Interview re Results - courtesy of SimonHatcher on LSE

[channel pirate] 02/6/2017 09:15

Still holding on to the shares I hold even though the Results are somewhat disappointing. Don’t think I will buy anymore just yet but will await the inevitable “cash call” later in the year before adding again.

[rayrac] 02/6/2017 08:09

The co seems to be top heavy with employees and, I would think a start-up co ideally starts with too few and builds up that part of the business in reaction to demand for product? But there we go, it's not run by me!👉🏿;😂

[bamboo2] 02/6/2017 08:01

I guess we'll have to wait to see, as Igbert says, they'll want to try to a multi-purpose fund raise. This will prob have to wait until the cost of the t/o is known.

The t/o is at least partly to do with the lack of viable human donor tissue in the US.
To me, this makes the launch of XT products in the US pivotal to increasing revenue.

[rayrac] 02/6/2017 07:59

That's some conundrum, pug!

[pugugly] 02/6/2017 07:48

OK Probably a placing necessary but at what price ?

[rayrac] 02/6/2017 07:42

Well, there they are! But I could find no mention of proposed t/o...or indeed where the cash will come from for said t/o?

They have a fairly large, 80, number of employees, including 7 directors and that takes a whopping great chunk out of finances! Which means they'll have to raise more cash well before year end.

But what bothered me most, was the potential lack of material for their wound care operations, mainly, it appears, in Germany/Europe?

[igbertsponk] 31/5/2017 15:19

Suspect they'll want to issue the results, an announcement on the deal, and an announcement on how they'll raise the cash to pay for it, all in one go.

[grahamburn] 31/5/2017 14:57

The potential acquisition would, of course, be a post year end event, but just wonder whether it is hoped that an announcement on this can be made at the same time as the prelims. Hence the delay.

[channel pirate] 31/5/2017 14:15

bamboo2,

Re Prelims, then I can't get any response from the Company, so talked to their Broker, Jefferies International, this afternoon and they were more helpful - TRX have to announce their Prelims by 7th June 2017 so by this time next week - watch this space then !!

[rayrac] 31/5/2017 11:36

Ditto eh?

I've just been buying in a small way, in bits and pieces. 10% only though of my original holding...but it's a start?

Btw, if it's inside info restricted, I bet there's a way! No emails, no phones, just man to man...or woman of course!

[channel pirate] 31/5/2017 11:02

RNS Number : 6845G

Tissue Regenix Group PLC

31 May 2017

Tissue Regenix Group plc

Potential Acquisition Update

Leeds, 31 May 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, notes the recent dissolution of the temporary restraining order ("TRO") issued by Bexar County District Court against CellRight Technologies, LLC ("CellRight"), a US regenerative medicine business based in San Antonio, Texas, in relation to a potential sale of CellRight to Tissue Regenix. Tissue Regenix confirms that it remains in discussions with CellRight regarding a possible acquisition of CellRight by Tissue Regenix. There can be no certainty at this stage that the discussions between the Group and CellRight will lead to an acquisition.

A further announcement will be made when appropriate.

This announcement contains inside information.

For more Information:

Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Corporate Communications 430 3073
Director
========================================== ===========
Jefferies International Ltd Tel: 020
Simon Hardy / Harry Nicholas 7029 8000
FTI Consulting Tel: 020
Brett Pollard / Mo Noonan 3727 1000

[bamboo2] 31/5/2017 11:01

31 May 2017

Tissue Regenix Group plc

Potential Acquisition Update

Leeds, 31 May 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, notes the recent dissolution of the temporary restraining order ("TRO") issued by Bexar County District Court against CellRight Technologies, LLC ("CellRight"), a US regenerative medicine business based in San Antonio, Texas, in relation to a potential sale of CellRight to Tissue Regenix. Tissue Regenix confirms that it remains in discussions with CellRight regarding a possible acquisition of CellRight by Tissue Regenix. There can be no certainty at this stage that the discussions between the Group and CellRight will lead to an acquisition.

A further announcement will be made when appropriate

[bamboo2] 31/5/2017 10:43

I guess management haven't managed to keep up with the calendar on their website.

I suppose there is still the rest of the day in theory.

[bamboo2] 29/5/2017 17:17

Thanks channel and graham.

An interesting few months coming up!

Starts this week.

[grahamburn] 29/5/2017 14:31

IMO the major shareholders CANNOT have been briefed as that would constitute inside information to selected shareholders.

That's not to say that there hasn't been an informal comment on the general idea or even "What would your reaction be were we to pursue this course of action?"

[channel pirate] 29/5/2017 07:49

Morning bamboo2,

Guessing, then the new Holdings Company has been inaugurated to acquire acquisitions the Main Company has in their sights as being beneficial to the Main Company – hence the recent RNS regarding CellRight Technologies, LLC ("CellRight").

To me then this indicates the Company is getting “stronger̶1; all round and is expanding, generating more income etc, both of which has not yet been updated to the market.

I would expect the large shareholders (Invesco, Woodford etc) are already briefed what is happening, especially with the share price languishing at the present low price, which must have knocked millions off the value of their holdings.

I’m looking forward to the Prelims, and let’s hope it reassures us small pi’s also that we have “boarded the right train”.